#1 Clinical Trials Search in Europe

Bms-986458

A groundbreaking clinical trial is underway to assess the potential of BMS-986458, a novel drug designed to target relapsed/refractory Non-Hodgkin Lymphoma. This study aims to explore the safety, effectiveness, and biological impact of BMS-986458, both as a standalone treatment and in combination with other anti-lymphoma medications. The trial offers new possibilities for patients who have not responded well to previous treatments, potentially paving the way for improved outcomes in lymphoma care.

Table of Contents

What is BMS-986458?

BMS-986458 is a new drug being studied for the treatment of relapsed/refractory non-Hodgkin lymphoma. It is classified as a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6. While this may sound complex, it essentially means that BMS-986458 is designed to target and break down a specific protein (BCL6) that plays a role in lymphoma development.[1]

Target Condition: Relapsed/Refractory Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (NHL) is a type of cancer that affects the lymphatic system, which is part of the body’s immune system. “Relapsed” means the cancer has returned after treatment, while “refractory” indicates that the cancer has not responded to treatment. Patients with relapsed or refractory NHL often have limited treatment options, which is why new drugs like BMS-986458 are being developed and studied.[1]

How BMS-986458 Works

BMS-986458 targets a protein called BCL6, which is known to play a role in the development and progression of certain types of lymphoma. By breaking down this protein, the drug aims to stop or slow the growth of cancer cells. This approach is different from traditional chemotherapy and may offer new hope for patients who have not responded to other treatments.[1]

Current Clinical Trial

A clinical trial is currently underway to evaluate BMS-986458. This trial is described as a Phase 1/2, multi-center, open-label, dose-finding study. Here’s what these terms mean:

  • Phase 1/2: This early stage of testing focuses on finding the right dose and assessing safety.
  • Multi-center: The study is being conducted at multiple hospitals or research centers.
  • Open-label: Both the researchers and participants know which treatment is being used.
  • Dose-finding: Researchers are trying to determine the best dose of the drug to use.

The main goals of this study are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMS-986458. In simpler terms, researchers want to know if the drug is safe, how well it’s tolerated by patients, how it moves through the body, how it affects the body, and whether it shows early signs of being effective against the cancer.[1]

Safety and Efficacy Measures

The study will closely monitor several aspects of patient health and treatment response:

  1. Adverse events (AEs): Any unfavorable changes in health that occur during the study.
  2. Serious adverse events (SAEs): AEs that are life-threatening or require hospitalization.
  3. Dose-limiting toxicities (DLTs): Side effects that are severe enough to prevent increasing the dose.
  4. Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  5. Duration of response (DOR): How long the cancer remains controlled after treatment.
  6. Progression-free survival (PFS): How long patients live without their cancer getting worse.
  7. Overall survival (OS): How long patients live after starting treatment.

These measures will help researchers determine if BMS-986458 is safe and effective for treating relapsed/refractory non-Hodgkin lymphoma.[1]

Combination Therapy

The study is also exploring the use of BMS-986458 in combination with other anti-lymphoma agents. One such agent mentioned is rituximab, a well-established drug used in the treatment of certain types of lymphoma. Combination therapy is often used in cancer treatment to potentially enhance effectiveness by attacking cancer cells through multiple mechanisms.[1]

This approach of testing BMS-986458 both alone and in combination with other drugs demonstrates the researchers’ commitment to finding the most effective treatment strategy for patients with relapsed/refractory non-Hodgkin lymphoma.

Aspect Details
Study Drug BMS-986458 (BCL6 LDD)
Target Condition Relapsed/Refractory Non-Hodgkin Lymphoma
Study Type Phase 1/2, Multi-Center, Open-Label, Dose-Finding
Treatment Approaches BMS-986458 alone and in combination with anti-lymphoma agents
Primary Outcomes Safety measures (AEs, SAEs, DLTs, discontinuations, deaths)
Secondary Outcomes Pharmacokinetics (Cmax, Tmax, AUC), Efficacy measures (ORR, DOR, TTR, PFS, OS)
Study Duration Up to 2 years and 1 month

FAQ

  • What is BMS-986458 and how does it work? BMS-986458 is a new drug called a bifunctional cereblon-dependent ligand-directed degrader (LDD) of BCL6. It works by targeting and breaking down a protein called BCL6, which is often involved in lymphoma development. This unique approach may help fight cancer cells in a way that other treatments haven't been able to.
  • Who is eligible for this clinical trial? This trial is designed for patients with relapsed/refractory Non-Hodgkin Lymphoma. This means people whose lymphoma has either come back after initial treatment or hasn't responded well to previous treatments.
  • What are the main goals of this study? The primary goals are to evaluate the safety and tolerability of BMS-986458, understand how the drug behaves in the body (pharmacokinetics), assess its biological effects (pharmacodynamics), and get early insights into its effectiveness against lymphoma.
  • How long will the study last? The study is planned to last up to 2 years and 1 month. During this time, researchers will closely monitor participants for any side effects and track the drug's effectiveness.
  • Will BMS-986458 be used alone or with other treatments? The study will evaluate BMS-986458 both as a single agent and in combination with other anti-lymphoma drugs. This approach helps researchers understand how the drug works on its own and how it might enhance the effects of existing treatments.

Ongoing Clinical Trials on Bms-986458

  • Study on BMS-986458 and Rituximab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany The Netherlands Spain

Glossary

  • Non-Hodgkin Lymphoma (NHL): A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
  • Relapsed/Refractory: Relapsed means the cancer has returned after treatment. Refractory means the cancer has not responded well to treatment.
  • BCL6: A protein that plays a role in the development of some types of lymphoma.
  • Bifunctional cereblon-dependent ligand-directed degrader (LDD): A type of drug that works by causing the breakdown of specific proteins in cancer cells.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Dose-limiting toxicity (DLT): Side effects that are severe enough to prevent increasing the dose of a drug in a clinical trial.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Duration of response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.

References

  1. https://clinicaltrials.gov/study/NCT06090539